Donald Trump’s proposed 200% tariff on generic drug imports is less a blow to India’s pharmaceutical industry than a costly gamble that could leave American patients paying the highest price.
President Donald Trump has consistently demonstrated a preference for maintaining control over escalation rather than allowing events to dictate American strategy.
It is unacceptable that the future of Mexico would depend on the constant changes of opinion of a president who still has 2 1/2 years of governing left.